As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Schrödinger Inc.'s stock soared 9% early Tuesday, after the company said it has entered a multi-year collaboration agreement with Swiss pharma Novartis AG. Under the terms of the deal, Schrödinger ...

Thomas also held leadership posts with Novartis, Bristol-Myers Squibb ... to advance to this critical stage of research,” ...

During John’s tenure as CEO, Anthos achieved successful fundraises with key sector ... Prior to Anthos, John held senior ...

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

Emerging from the rough waters of the CDMO industry with a new chief executive at the helm, AGC Biologics is on a mission to reinvent itself as a manufacturing partner defined by friendliness and e | ...

The recently announced global license agreement with Novartis to advance VAV1-directed MGDs for immune-related conditions marks a transformative milestone towards that goal,” said Markus Warmuth, M.D.